Treatment of vitamin D deficiency in cystic fibrosis

J Steroid Biochem Mol Biol. 2016 Nov:164:36-39. doi: 10.1016/j.jsbmb.2015.09.013. Epub 2015 Sep 10.

Abstract

Vitamin D deficiency occurs frequently in patients with cystic fibrosis (CF). Vitamin D is important for optimal mineralization of bone and may be important for other comorbidities commonly occurring in patients with CF. Vitamin D deficiency in patients with CF can arise from various causes including pancreatic exocrine insufficiency, lack of outdoor activity, and alterations of vitamin D metabolism. Due to fat malabsorption stemming from pancreatic insufficiency, higher oral doses of vitamin D are necessary to correct and maintain optimal vitamin D status in patients with CF. Recent studies have demonstrated that higher vitamin D status is associated with better lung function and that vitamin D therapy may help recovery from pulmonary exacerbations of CF. The mechanisms by which vitamin D may exert its beneficial actions in CF are unclear but likely related to the role vitamin D has in modulating the adaptive and innate immune response. Large randomized clinical studies to evaluate the potential role of vitamin D as adjunctive therapy in CF that goes beyond bone are necessary.

Publication types

  • Review

MeSH terms

  • Bone Diseases / complications
  • Cholecalciferol / therapeutic use
  • Clinical Trials as Topic
  • Comorbidity
  • Cystic Fibrosis / complications*
  • Cystic Fibrosis / therapy*
  • Ergocalciferols / chemistry
  • Ergocalciferols / therapeutic use
  • Humans
  • Inflammation
  • Lung / metabolism
  • Lung / physiology
  • Randomized Controlled Trials as Topic
  • Respiratory Function Tests
  • Vitamin D / analogs & derivatives
  • Vitamin D / blood
  • Vitamin D / therapeutic use*
  • Vitamin D Deficiency / complications*
  • Vitamin D Deficiency / therapy*

Substances

  • Ergocalciferols
  • Vitamin D
  • Cholecalciferol
  • 25-hydroxyvitamin D